Celularity (NASDAQ:CELU) Announces Quarterly Earnings Results

Celularity (NASDAQ:CELU) issued its quarterly earnings data on Friday. The company reported ($0.88) EPS for the quarter, Zacks reports. Celularity had a negative return on equity of 459.57% and a negative net margin of 165.22%.

Celularity Stock Down 2.5%

Celularity stock traded down $0.04 during mid-day trading on Friday, reaching $1.55. 137,656 shares of the company’s stock were exchanged, compared to its average volume of 65,325. The company has a fifty day moving average of $2.03 and a 200-day moving average of $2.34. The company has a market cap of $41.37 million, a P/E ratio of -0.49 and a beta of 0.76. Celularity has a twelve month low of $1.00 and a twelve month high of $4.35.

Hedge Funds Weigh In On Celularity

Several large investors have recently bought and sold shares of CELU. Vanguard Group Inc. grew its position in shares of Celularity by 35.3% in the 3rd quarter. Vanguard Group Inc. now owns 676,650 shares of the company’s stock valued at $1,401,000 after buying an additional 176,518 shares during the last quarter. Bank of America Corp DE boosted its stake in Celularity by 1,538.1% in the second quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock valued at $73,000 after acquiring an additional 35,023 shares in the last quarter. XTX Topco Ltd grew its holdings in shares of Celularity by 106.4% during the second quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock worth $42,000 after purchasing an additional 11,057 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new stake in shares of Celularity during the first quarter worth about $34,000. Hedge funds and other institutional investors own 19.02% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on CELU shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Celularity in a research report on Wednesday, October 8th. Wall Street Zen lowered shares of Celularity from a “hold” rating to a “sell” rating in a research note on Friday, September 5th. Finally, WBB Securities upgraded Celularity from a “hold” rating to a “buy” rating and set a $6.00 target price on the stock in a research report on Tuesday, September 9th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $6.00.

About Celularity

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.